Interactive Exchangeā„¢

Pathways to Better Outcomes in Systemic Lupus Erythematosus

Translating Pathophysiology into Targeted Treatments

Meeting Slides

Suggested Readings

American College of Rheumatology (ACR) Annual Meeting Abstracts.

October 19th-24th, 2018. Chicago, Illinios.

Personalized immunomonitoring uncovers molecular networks that stratify lupus patients.

Banchereau R, et al. Cell. 2016;165(3):551-565.

Diagnostic criteria for systemic lupus erythematosus: has the time come?

Bertsias GK, et al. Nat Rev Rheumatol. 2013;9(11):687-694.

Advances in understanding the role of type I interferons in systemic lupus erythematosus.

Crow MK. Curr Opin Rheumatol. 2014;26(5):467-474.

Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).

Franklyn K, et al. Ann Rheum Dis. 2016;75(9):1615-1621.

Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.

Furie R, et al. Arthritis Rheumatol. 2017;69(2):376-386.

A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits BLyS [B lymphocyte stimulator], in patients with systemic lupus erythematosus.

Furie R, et al. Arthritis Rheum. 2011;63(12):3918-3930.

The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus.

Lewis MJ, Jawad AS. Rheumatology (Oxford).

Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study.

Merrill JT, et al. Arthritis Rheumatol. 2018;70(2):266-276.

Connective tissue diseases: remission in SLE—are we there yet?

Morand EF. Nat Rev Rheumatol. 2016;12(12):696-698.

Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the phase IIb MUSE trial of anifrolumab.

Morand EF, et al. Ann Rheum Dis. 2018;77(5):706-713.

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Navarra SV, et al. Lancet. 2011;377(9767):721-731.

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.

van Vollenhoven RF, et al. Ann Rheum Dis. 2014;73(6):958-967.

Comparison of remission and Lupus Low Disease Activity State in damage prevention in a United States systemic lupus erythematosus cohort.

Petri M, Magder LS. Arthritis Rheumatol. May 2018. [Epub ahead of print].

Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial.

Zimmer R, et al. Ann Rheum Dis. 2013;72(11):1830-1835.

Interactive Presentation

Insights Into Pathogenic Mechanisms in SLE

Virginia Pascual, MD

Relevant Resources

Clinical Updates in Systemic Lupus Erythematosus

Improved Diagnostic and Management Strategies

Advances in Immunosupressive Therapy for Solid Organ Transplantation

Long-Term Management Strategies to Improve Patient Outcomes

Clinical Updates on the Management of Gout

Evidence-Based Strategies for Improved Patient Outcomes

Managing Gout in Primary Care

Evolving Strategies for Diagnosis and Long-Term Management

Improving Outcomes in Rheumatoid Arthritis

Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms

Clinical Updates in Rheumatoid Arthritis

Evolving Treatment Algorithms and Expert Perspectives on Biosimilars

Going Deeper on Atopic Dermatitis

Pathophysiology to the Management of Moderate-to-Severe Disease

Looking Beneath The Surface In Atopic Dermatitis

Targeting Immune Dysregulation and Delivering Comprehensive Care

Evolving Treatment Paradigms For Rheumatoid Arthritis

Translating Comprehensive Patient Evaluations Into Personalized Therapy

Clinical Updates in Rheumatoid Arthritis

New Perspectives on Targeting Remission and Individualizing Therapy

A Better Look at Rheumatoid Arthritis

Using Imaging to Improve Patient Outcomes

Clinical Issues in Rheumatoid Arthritis

Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs